Targeting EZH2 for Cancer Therapy: Progress and Perspective

Title:Targeting EZH2 for Cancer Therapy: Progress and Perspective

Volume: 16 Issue: 6

Author(s): Chi Han Li and Yangchao Chen

Affiliation:

Keywords: Chemotherapy, DNA methylation, DZNep, EZH2, H3K27me3, LncRNA, PRC2, SET domain.

Abstract: Enhancer of Zeste Homolog 2 (EZH2) is the core component of the polycomb repressive complex 2 (PRC2), possessing the enzymatic activity in generating di/tri-methylated lysine 27 in histone H3. EZH2 has important roles during early development, and its dysregulation is heavily linked to oncogenesis in various tissue types. Accumulating evidences suggest a remarkable therapeutic potential by targeting EZH2 in cancer cells. The first part reviews current strategies to target EZH2 in cancers, and evaluates the available compounds and agents used to disrupt EZH2 functions. Then we provide insight to the future direction of the research on targeting EZH2 in different cancer types. We comprehensively discuss the current understandings of the 1) structure and biological activity of EZH2, 2) its role during the assembling of PRC2 and recruitment of other protein components, 3) the molecular events directing EZH2 to target genomic regions, and 4) post-translational modification at EZH2 protein. The discussion provides the basis to inspire the development of novel strategies to abolish EZH2-related effects in cancer cells.

Cite this article as:

Han Li Chi and Chen Yangchao, Targeting EZH2 for Cancer Therapy: Progress and Perspective, Current Protein & Peptide Science 2015; 16 (6) . https://dx.doi.org/10.2174/1389203716666150409100233